Published in J Biol Chem on June 09, 2008
Targeting metabolic transformation for cancer therapy. Nat Rev Cancer (2010) 5.90
HIF-1: upstream and downstream of cancer metabolism. Curr Opin Genet Dev (2009) 5.24
Adaptive and maladaptive cardiorespiratory responses to continuous and intermittent hypoxia mediated by hypoxia-inducible factors 1 and 2. Physiol Rev (2012) 2.24
Erk regulation of pyruvate dehydrogenase flux through PDK4 modulates cell proliferation. Genes Dev (2011) 2.20
A STAT3-mediated metabolic switch is involved in tumour transformation and STAT3 addiction. Aging (Albany NY) (2010) 1.70
Glutamine deprivation induces abortive s-phase rescued by deoxyribonucleotides in k-ras transformed fibroblasts. PLoS One (2009) 1.58
Oxygen consumption can regulate the growth of tumors, a new perspective on the Warburg effect. PLoS One (2009) 1.52
Acidic extracellular microenvironment and cancer. Cancer Cell Int (2013) 1.47
Wnt signaling directs a metabolic program of glycolysis and angiogenesis in colon cancer. EMBO J (2014) 1.43
Pyruvate dehydrogenase kinase as a novel therapeutic target in oncology. Front Oncol (2013) 1.42
Mitochondrial Akt Regulation of Hypoxic Tumor Reprogramming. Cancer Cell (2016) 1.41
Monitoring phosphorylation of the pyruvate dehydrogenase complex. Anal Biochem (2009) 1.38
A role for the mitochondrial pyruvate carrier as a repressor of the Warburg effect and colon cancer cell growth. Mol Cell (2014) 1.34
TKTL1 is activated by promoter hypomethylation and contributes to head and neck squamous cell carcinoma carcinogenesis through increased aerobic glycolysis and HIF1alpha stabilization. Clin Cancer Res (2010) 1.27
Quantitative proteomics identification of phosphoglycerate mutase 1 as a novel therapeutic target in hepatocellular carcinoma. Mol Cancer (2010) 1.24
Glucose, not glutamine, is the dominant energy source required for proliferation and survival of head and neck squamous carcinoma cells. Cancer (2011) 1.21
Anticancer agents that counteract tumor glycolysis. ChemMedChem (2012) 1.17
Hypoxic regulation of glutamine metabolism through HIF1 and SIAH2 supports lipid synthesis that is necessary for tumor growth. Cell Metab (2014) 1.15
Metabolism and brain cancer. Clinics (Sao Paulo) (2011) 1.10
Relevance of mitochondrial genetics and metabolism in cancer development. Cold Spring Harb Perspect Biol (2013) 1.08
SIRT3 deacetylates and increases pyruvate dehydrogenase activity in cancer cells. Free Radic Biol Med (2014) 1.07
mTORC2 in the center of cancer metabolic reprogramming. Trends Endocrinol Metab (2014) 1.05
Overexpression of pyruvate dehydrogenase kinase 3 increases drug resistance and early recurrence in colon cancer. Am J Pathol (2011) 1.02
Emerging metabolic targets in cancer therapy. Front Biosci (Landmark Ed) (2011) 1.02
Individualizing antimetabolic treatment strategies for head and neck squamous cell carcinoma based on TP53 mutational status. Cancer (2011) 1.00
Metabolic restructuring during energy-limited states: insights from Artemia franciscana embryos and other animals. J Insect Physiol (2011) 1.00
Metformin sensitizes anticancer effect of dasatinib in head and neck squamous cell carcinoma cells through AMPK-dependent ER stress. Oncotarget (2014) 0.99
Is cancer a metabolic disease? Am J Pathol (2013) 0.99
Mitochondria and energetic depression in cell pathophysiology. Int J Mol Sci (2009) 0.95
Modeling core metabolism in cancer cells: surveying the topology underlying the Warburg effect. PLoS One (2010) 0.95
Amyloid beta resistance in nerve cell lines is mediated by the Warburg effect. PLoS One (2011) 0.94
Sub-sets of cancer stem cells differ intrinsically in their patterns of oxygen metabolism. PLoS One (2013) 0.94
Inducible overexpression of GLUT1 prevents mitochondrial dysfunction and attenuates structural remodeling in pressure overload but does not prevent left ventricular dysfunction. J Am Heart Assoc (2013) 0.93
A phase I study of the first-in-class antimitochondrial metabolism agent, CPI-613, in patients with advanced hematologic malignancies. Clin Cancer Res (2014) 0.93
Restoration of mitochondria function as a target for cancer therapy. Drug Discov Today (2015) 0.93
A novel model of common Toll-like receptor 4- and injury-induced transcriptional themes in human leukocytes. Crit Care (2010) 0.91
Mitochondria-mediated energy adaption in cancer: the H(+)-ATP synthase-geared switch of metabolism in human tumors. Antioxid Redox Signal (2012) 0.91
Small mitochondria-targeting molecules as anti-cancer agents. Mol Aspects Med (2009) 0.91
Canonical and non-canonical Hedgehog signalling and the control of metabolism. Semin Cell Dev Biol (2014) 0.89
PDK4 protein promotes tumorigenesis through activation of cAMP-response element-binding protein (CREB)-Ras homolog enriched in brain (RHEB)-mTORC1 signaling cascade. J Biol Chem (2014) 0.88
SIRT3 regulates progression and development of diseases of aging. Trends Endocrinol Metab (2015) 0.88
Expression parameters of the metabolic pathway genes pyruvate dehydrogenase kinase-1 (PDK-1) and DJ-1/PARK7 in renal cell carcinoma (RCC). World J Urol (2012) 0.87
Molecular Pathways: Mitochondrial Reprogramming in Tumor Progression and Therapy. Clin Cancer Res (2015) 0.86
Drugging the addict: non-oncogene addiction as a target for cancer therapy. EMBO Rep (2016) 0.84
Analysis and interpretation of transcriptomic data obtained from extended Warburg effect genes in patients with clear cell renal cell carcinoma. Oncoscience (2015) 0.84
Targeting of two aspects of metabolism in breast cancer treatment. Cancer Biol Ther (2014) 0.83
Chronic CSE treatment induces the growth of normal oral keratinocytes via PDK2 upregulation, increased glycolysis and HIF1α stabilization. PLoS One (2011) 0.83
VER-246608, a novel pan-isoform ATP competitive inhibitor of pyruvate dehydrogenase kinase, disrupts Warburg metabolism and induces context-dependent cytostasis in cancer cells. Oncotarget (2014) 0.83
Novel therapeutic targets of tumor metabolism. Cancer J (2015) 0.82
Serum lactate dehydrogenase and survival following cancer diagnosis. Br J Cancer (2015) 0.82
Altered metabolism in head and neck squamous cell carcinoma: an opportunity for identification of novel biomarkers and drug targets. Head Neck (2011) 0.82
Linking vitamin B1 with cancer cell metabolism. Cancer Metab (2013) 0.82
Dual-targeting of aberrant glucose metabolism in glioblastoma. J Exp Clin Cancer Res (2015) 0.82
Dichloroacetate, a selective mitochondria-targeting drug for oral squamous cell carcinoma: a metabolic perspective of treatment. Oncotarget (2015) 0.82
Pyruvate Dehydrogenase Kinases in the Nervous System: Their Principal Functions in Neuronal-glial Metabolic Interaction and Neuro-metabolic Disorders. Curr Neuropharmacol (2012) 0.80
Targeting Tumor Metabolism for Cancer Treatment: Is Pyruvate Dehydrogenase Kinases (PDKs) a Viable Anticancer Target? Int J Biol Sci (2015) 0.80
Systems biology of cancer: moving toward the integrative study of the metabolic alterations in cancer cells. Front Physiol (2013) 0.79
Pyruvate Dehydrogenase Kinases: Therapeutic Targets for Diabetes and Cancers. Diabetes Metab J (2015) 0.79
Hypoxic regulation of metabolism offers new opportunities for anticancer therapy. Expert Rev Anticancer Ther (2014) 0.79
Deciphering squamous cell carcinoma using multidimensional genomic approaches. J Skin Cancer (2010) 0.79
ZBTB2 increases PDK4 expression by transcriptional repression of RelA/p65. Nucleic Acids Res (2015) 0.79
AMPK activation--protean potential for boosting healthspan. Age (Dordr) (2013) 0.78
Quantitative measurement of organic acids in tissues from gastric cancer patients indicates increased glucose metabolism in gastric cancer. PLoS One (2014) 0.78
Hypoxic repression of pyruvate dehydrogenase activity is necessary for metabolic reprogramming and growth of model tumours. Sci Rep (2016) 0.77
High-dose vitamin B1 reduces proliferation in cancer cell lines analogous to dichloroacetate. Cancer Chemother Pharmacol (2014) 0.77
Current relevance of hypoxia in head and neck cancer. Oncotarget (2016) 0.76
MicroRNA-126 induces autophagy by altering cell metabolism in malignant mesothelioma. Oncotarget (2016) 0.76
Differential inhibition of PDKs by phenylbutyrate and enhancement of pyruvate dehydrogenase complex activity by combination with dichloroacetate. J Inherit Metab Dis (2015) 0.76
Annexin A1 sustains tumor metabolism and cellular proliferation upon stable loss of HIF1A. Oncotarget (2016) 0.76
Silencing gastrin-releasing peptide receptor suppresses key regulators of aerobic glycolysis in neuroblastoma cells. Pediatr Blood Cancer (2015) 0.76
PDHA1 gene knockout in prostate cancer cells results in metabolic reprogramming towards greater glutamine dependence. Oncotarget (2016) 0.76
Molecular mechanisms of hypoxia in cancer. Clin Transl Imaging (2017) 0.75
Biophysical insights into cancer transformation and treatment. ScientificWorldJournal (2013) 0.75
PDK2-mediated alternative splicing switches Bnip3 from cell death to cell survival. J Cell Biol (2015) 0.75
Alterations in Red Blood Cell Functionality Induced by an Indole Scaffold Containing a Y-Iminodiketo Moiety: Potential Antiproliferative Conditions. Oxid Med Cell Longev (2016) 0.75
Differing roles of pyruvate dehydrogenase kinases during mouse oocyte maturation. J Cell Sci (2015) 0.75
Thermodynamics in cancers: opposing interactions between PPAR gamma and the canonical WNT/beta-catenin pathway. Clin Transl Med (2017) 0.75
A metabolic switch controls intestinal differentiation downstream of Adenomatous polyposis coli (APC). Elife (2017) 0.75
Increasing Superoxide Production and the Labile Iron Pool in Tumor Cells may Sensitize Them to Extracellular Ascorbate. Front Oncol (2014) 0.75
Oncogenic role of PDK4 in human colon cancer cells. Br J Cancer (2017) 0.75
Mitochondrial pyruvate carrier function and cancer metabolism. Curr Opin Genet Dev (2016) 0.75
Src drives the Warburg effect and therapy resistance by inactivating pyruvate dehydrogenase through tyrosine-289 phosphorylation. Oncotarget (2016) 0.75
Gluconeogenesis, lipogenesis, and HBV replication are commonly regulated by PGC-1α-dependent pathway. Oncotarget (2015) 0.75
Global Kinetic Analysis of Mammalian E3 Reveals pH-dependent NAD+/NADH Regulation, Physiological Kinetic Reversibility, and Catalytic Optimum. J Biol Chem (2015) 0.75
Interactions between PPAR Gamma and the Canonical Wnt/Beta-Catenin Pathway in Type 2 Diabetes and Colon Cancer. PPAR Res (2017) 0.75
Resveratrol reverses the Warburg effect by targeting the pyruvate dehydrogenase complex in colon cancer cells. Sci Rep (2017) 0.75
Overexpression of the human DEK oncogene reprograms cellular metabolism and promotes glycolysis. PLoS One (2017) 0.75
Overexpression of pyruvate dehydrogenase kinase 1 in retinoblastoma: A potential therapeutic opportunity for targeting vitreous seeds and hypoxic regions. PLoS One (2017) 0.75
Thermodynamics in Gliomas: Interactions between the Canonical WNT/Beta-Catenin Pathway and PPAR Gamma. Front Physiol (2017) 0.75
Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science (2001) 23.83
Hypoxia--a key regulatory factor in tumour growth. Nat Rev Cancer (2002) 20.51
The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab (2008) 18.87
HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab (2006) 13.22
HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab (2006) 10.14
Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell (2006) 9.80
Akt stimulates aerobic glycolysis in cancer cells. Cancer Res (2004) 9.35
Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell (2005) 9.33
A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell (2007) 9.20
p53 regulates mitochondrial respiration. Science (2006) 9.06
Detecting tumor response to treatment using hyperpolarized 13C magnetic resonance imaging and spectroscopy. Nat Med (2007) 6.84
Metabolic imaging by hyperpolarized 13C magnetic resonance imaging for in vivo tumor diagnosis. Cancer Res (2006) 5.79
HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell (2005) 5.47
c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc Natl Acad Sci U S A (1997) 5.43
Probabilistic quotient normalization as robust method to account for dilution of complex biological mixtures. Application in 1H NMR metabonomics. Anal Chem (2006) 4.29
Mitochondrial tumour suppressors: a genetic and biochemical update. Nat Rev Cancer (2005) 3.85
Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis. J Biol Chem (2002) 3.50
Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia. PLoS Med (2006) 2.95
Inhibition of hypoxia-inducible factor (HIF) hydroxylases by citric acid cycle intermediates: possible links between cell metabolism and stabilization of HIF. J Biol Chem (2006) 2.86
Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood (2007) 2.64
Regulation of the pyruvate dehydrogenase complex. Biochem Soc Trans (2006) 2.28
Multiple factors affecting cellular redox status and energy metabolism modulate hypoxia-inducible factor prolyl hydroxylase activity in vivo and in vitro. Mol Cell Biol (2006) 2.27
Reversible inactivation of HIF-1 prolyl hydroxylases allows cell metabolism to control basal HIF-1. J Biol Chem (2005) 2.19
Effect of ascorbate on the activity of hypoxia-inducible factor in cancer cells. Cancer Res (2003) 1.99
Pyruvate dehydrogenase kinase regulatory mechanisms and inhibition in treating diabetes, heart ischemia, and cancer. Cell Mol Life Sci (2007) 1.87
Structural and mechanistic studies on the inhibition of the hypoxia-inducible transcription factor hydroxylases by tricarboxylic acid cycle intermediates. J Biol Chem (2006) 1.75
Lactate in solid malignant tumors: potential basis of a metabolic classification in clinical oncology. Curr Med Chem (2004) 1.74
Ras inhibition in glioblastoma down-regulates hypoxia-inducible factor-1alpha, causing glycolysis shutdown and cell death. Cancer Res (2005) 1.73
Frequency and phenotypic implications of mitochondrial DNA mutations in human squamous cell cancers of the head and neck. Proc Natl Acad Sci U S A (2007) 1.68
Metabolic targeting of hypoxia and HIF1 in solid tumors can enhance cytotoxic chemotherapy. Proc Natl Acad Sci U S A (2007) 1.63
Dichloroacetate effects on glucose and lactate oxidation by neurons and astroglia in vitro and on glucose utilization by brain in vivo. Proc Natl Acad Sci U S A (2003) 1.55
Hypoxia-inducible factor (HIF) in human tumorigenesis. Histol Histopathol (2007) 1.52
Aerobically derived lactate stimulates revascularization and tissue repair via redox mechanisms. Antioxid Redox Signal (2007) 1.45
Mitochondrial impairment in p53-deficient human cancer cells. Mutagenesis (2003) 1.22
Lung cancer: a comparative study of metabolism related protein expression in cancer cells and tumor associated stroma. Cancer Biol Ther (2007) 1.18
Polymorphism- and species-dependent inactivation of glutathione transferase zeta by dichloroacetate. Chem Res Toxicol (2000) 1.14
Angiogenic activity of pyruvic acid in in vivo and in vitro angiogenesis models. Cancer Res (2001) 1.06
Dichloroacetate. Diabetes Care (1992) 0.95
Assay of the pyruvate dehydrogenase complex by coupling with recombinant chicken liver arylamine N-acetyltransferase. Anal Biochem (2006) 0.95
The induction of oxidative stress and cellular death by the drinking water disinfection by-products, dichloroacetate and trichloroacetate in J774.A1 cells. Comp Biochem Physiol C Toxicol Pharmacol (2003) 0.92
Role of the peroxisome proliferator-activated receptor alpha (PPARalpha) in responses to trichloroethylene and metabolites, trichloroacetate and dichloroacetate in mouse liver. Toxicology (2004) 0.91
A bioluminescence technique for quantitative and structure-associated imaging of pyruvate. Lab Invest (2006) 0.88
Differential effects of chromosome 3p deletion on the expression of the putative tumor suppressor RAR beta and on retinoid resistance in human squamous carcinoma cells. Oncogene (2001) 0.83
Formation of functional heterodimers by isozymes 1 and 2 of pyruvate dehydrogenase kinase. Biochim Biophys Acta (2003) 0.81
Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature (2006) 11.86
Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science (2011) 11.12
Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell (2003) 8.11
PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature (2006) 7.35
Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell (2007) 6.52
TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med (2007) 5.92
Attenuation of Pseudomonas aeruginosa virulence by quorum sensing inhibitors. EMBO J (2003) 5.78
PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. Cancer Cell (2003) 5.13
Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res (2005) 5.04
Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell (2003) 4.96
A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg (2010) 4.75
Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell (2011) 4.43
Double-strand break repair-independent role for BRCA2 in blocking stalled replication fork degradation by MRE11. Cell (2011) 4.41
BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab (2005) 4.39
Differential regulation of central nervous system autoimmunity by T(H)1 and T(H)17 cells. Nat Med (2008) 4.24
Cre/loxP-mediated inactivation of the murine Pten tumor suppressor gene. Genesis (2002) 4.23
PTEN-deficient intestinal stem cells initiate intestinal polyposis. Nat Genet (2007) 4.09
Pten haploinsufficiency accelerates formation of high-grade astrocytomas. Cancer Res (2008) 3.99
Deficiency or inhibition of oxygen sensor Phd1 induces hypoxia tolerance by reprogramming basal metabolism. Nat Genet (2008) 3.94
mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell (2009) 3.78
BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition. Nature (2011) 3.63
Proliferative neural stem cells have high endogenous ROS levels that regulate self-renewal and neurogenesis in a PI3K/Akt-dependant manner. Cell Stem Cell (2011) 3.56
Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis. J Biol Chem (2002) 3.50
Bmi-1 is a crucial regulator of prostate stem cell self-renewal and malignant transformation. Cell Stem Cell (2010) 3.41
Liver-specific deletion of negative regulator Pten results in fatty liver and insulin hypersensitivity [corrected]. Proc Natl Acad Sci U S A (2004) 3.40
Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents. J Cell Biol (2008) 3.36
Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation. Proc Natl Acad Sci U S A (2006) 3.34
Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database. Int J Cancer (2005) 3.27
A distinct replication fork protection pathway connects Fanconi anemia tumor suppressors to RAD51-BRCA1/2. Cancer Cell (2012) 3.26
Pten constrains centroacinar cell expansion and malignant transformation in the pancreas. Cancer Cell (2005) 3.15
In situ proteolysis for protein crystallization and structure determination. Nat Methods (2007) 3.05
Redundancy in the population code of the retina. Neuron (2005) 3.02
Cutaneous metastases from genitourinary malignancies. Urology (2004) 2.97
PTEN negatively regulates neural stem cell self-renewal by modulating G0-G1 cell cycle entry. Proc Natl Acad Sci U S A (2005) 2.93
The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response. J Immunol (2009) 2.68
Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury. Circulation (2003) 2.68
Comprehensive sampling of gene expression in human cell lines with massively parallel signature sequencing. Proc Natl Acad Sci U S A (2003) 2.64
Chordoma: current concepts, management, and future directions. Lancet Oncol (2012) 2.63
Alcohol consumption and expenditures for underage drinking and adult excessive drinking. JAMA (2003) 2.59
MicroRNA alterations in head and neck squamous cell carcinoma. Int J Cancer (2008) 2.56
PIAS1 selectively inhibits interferon-inducible genes and is important in innate immunity. Nat Immunol (2004) 2.52
Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol (2002) 2.51
Lin-Sca-1+CD49fhigh stem/progenitors are tumor-initiating cells in the Pten-null prostate cancer model. Cancer Res (2009) 2.49
A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. Cancer Cell (2008) 2.48
Multi-genetic events collaboratively contribute to Pten-null leukaemia stem-cell formation. Nature (2008) 2.47
Neuropathology provides clues to the pathophysiology of Gaucher disease. Mol Genet Metab (2004) 2.46
Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. Cancer Res (2012) 2.45
Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN. Cancer Cell (2007) 2.43
Conditional loss of PTEN leads to precocious development and neoplasia in the mammary gland. Development (2002) 2.42
Increased expression of stem cell markers in malignant melanoma. Mod Pathol (2006) 2.39
Impact of pharyngeal closure technique on fistula after salvage laryngectomy. JAMA Otolaryngol Head Neck Surg (2013) 2.37
PTENless means more. Dev Biol (2004) 2.31
NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer initiation caused by PTEN loss. Cancer Cell (2006) 2.29
Modulation of prostate cancer genetic risk by omega-3 and omega-6 fatty acids. J Clin Invest (2007) 2.26
Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. Clin Cancer Res (2005) 2.22
Reversible inactivation of HIF-1 prolyl hydroxylases allows cell metabolism to control basal HIF-1. J Biol Chem (2005) 2.19
Enhanced paracrine FGF10 expression promotes formation of multifocal prostate adenocarcinoma and an increase in epithelial androgen receptor. Cancer Cell (2007) 2.14
Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. J Clin Oncol (2009) 2.13
PTEN dosage is essential for neurofibroma development and malignant transformation. Proc Natl Acad Sci U S A (2009) 2.07
Mitochondrial matrix phosphoproteome: effect of extra mitochondrial calcium. Biochemistry (2006) 2.06
Pten inactivation alters peripheral B lymphocyte fate and reconstitutes CD19 function. Nat Immunol (2003) 2.05
Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development. Cancer Res (2007) 2.04
A critical role of erythropoietin receptor in neurogenesis and post-stroke recovery. J Neurosci (2006) 2.04
Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice. J Clin Invest (2006) 2.03
Hepatocellular carcinoma: stiffness value and ratio to discriminate malignant from benign focal liver lesions. Radiology (2015) 2.03
Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysis. J Clin Oncol (2008) 1.97
DNA global hypomethylation in squamous cell head and neck cancer associated with smoking, alcohol consumption and stage. Int J Cancer (2007) 1.97
Mitochondrial C-tract alteration in premalignant lesions of the head and neck: a marker for progression and clonal proliferation. Clin Cancer Res (2002) 1.97
Cystic lymph node metastasis in patients with head and neck cancer: An HPV-associated phenomenon. Head Neck (2008) 1.97
Tissue heterogeneity of the mammalian mitochondrial proteome. Am J Physiol Cell Physiol (2006) 1.97
A detrimental mitochondrial-nuclear interaction causes cytoplasmic male sterility in rice. Nat Genet (2013) 1.92
Cyclin D1 and c-myc internal ribosome entry site (IRES)-dependent translation is regulated by AKT activity and enhanced by rapamycin through a p38 MAPK- and ERK-dependent pathway. J Biol Chem (2005) 1.89
JNK and PTEN cooperatively control the development of invasive adenocarcinoma of the prostate. Proc Natl Acad Sci U S A (2012) 1.88
Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. J Clin Oncol (2010) 1.88
The genomics of selection in dogs and the parallel evolution between dogs and humans. Nat Commun (2013) 1.86
Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Mol Cancer Ther (2008) 1.86
Three-dimensional nanostructured substrates toward efficient capture of circulating tumor cells. Angew Chem Int Ed Engl (2009) 1.86
Regulation of pyruvate dehydrogenase kinase expression by peroxisome proliferator-activated receptor-alpha ligands, glucocorticoids, and insulin. Diabetes (2002) 1.84
Steroid 5alpha-reductase isozymes I and II in recurrent prostate cancer. Clin Cancer Res (2005) 1.84
Impact of fluoroquinolone resistance mutations on gonococcal fitness and in vivo selection for compensatory mutations. J Infect Dis (2012) 1.83
Selectivity for multiple stimulus features in retinal ganglion cells. J Neurophysiol (2006) 1.81
12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy? Sci Rep (2012) 1.81
Pten deletion in adult neural stem/progenitor cells enhances constitutive neurogenesis. J Neurosci (2009) 1.80
Protein profiling with Epstein-Barr nuclear antigen-1 reveals an interaction with the herpesvirus-associated ubiquitin-specific protease HAUSP/USP7. J Biol Chem (2003) 1.78
Activation of NAD(P)H:quinone oxidoreductase 1 prevents arterial restenosis by suppressing vascular smooth muscle cell proliferation. Circ Res (2009) 1.75
Maternal embryonic leucine zipper kinase (MELK) regulates multipotent neural progenitor proliferation. J Cell Biol (2005) 1.74
Inverse correlation between cyclin A1 hypermethylation and p53 mutation in head and neck cancer identified by reversal of epigenetic silencing. Cancer Res (2004) 1.74
Suppression of nucleotide metabolism underlies the establishment and maintenance of oncogene-induced senescence. Cell Rep (2013) 1.74
Laparoscopy versus open distal gastrectomy for advanced gastric cancer: a systematic review and meta-analysis. Surg Laparosc Endosc Percutan Tech (2013) 1.72
Photodetectors based on intersubband transitions using III-nitride superlattice structures. J Phys Condens Matter (2009) 1.70
Frequency and phenotypic implications of mitochondrial DNA mutations in human squamous cell cancers of the head and neck. Proc Natl Acad Sci U S A (2007) 1.68
Consensus statement on the classification and terminology of neck dissection. Arch Otolaryngol Head Neck Surg (2008) 1.68
Endothelin receptor type B gene promoter hypermethylation in salivary rinses is independently associated with risk of oral cavity cancer and premalignancy. Cancer Prev Res (Phila) (2010) 1.68
Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. J Neurooncol (2011) 1.67
PTEN as an effector in the signaling of antimigratory G protein-coupled receptor. Proc Natl Acad Sci U S A (2005) 1.67
mTOR is activated in the majority of malignant melanomas. J Invest Dermatol (2007) 1.66